onc201
ONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline Glioma
2024 | Journal of Clinical Oncology
Chimerix is now part of Jazz Pharmaceuticals. Learn more at www.jazzpharma.com
ONC201 Publications
onc201
Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
2023 | Cancer Discovery
onc201
Role of ClpP in the Anti-cancer Effects of Imipridone ONC201 and ONC206
American Association for Cancer Research (AACR) Annual Meeting; April 14-19, 2023
onc201
ACTION: A randomized phase 3 study of dordaviprone (ONC201) in patients with newly diagnosed H3 K27M-mutant diffuse glioma
American Association for Cancer Research (AACR) Annual Meeting; April 14-19, 2023 –Orlando, FL
onc201
Safety of ONC201 administered two consecutive days per week in pediatric H3 K27M-mutant glioma patients
2021 SNO Annual Meeting Abstract CTNI-36
onc201
Clinical efficacy of ONC201 in recurrent H3 K27M-mutant diffuse midline glioma patients
2021 SNO Annual Conference
onc201
Epidermal growth factor receptor as a molecular determinant of glioblastoma response to dopamine receptor D2 inhibitors
Neuro Oncol. 2021 PMID: 32830856
onc201
A Bayesian machine learning approach for drug target identification using diverse data types
Nat Commun. 2019 PMID: 31745082
onc201
Biological activity of weekly ONC201 in adult recurrent glioblastoma patients
Neuro Oncol. 2020 PMID: 31702782
onc201
Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201
J Neurooncol. 2019 PMID: 31456142
